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A genome-wide association study (GWAS) has discovered that a polymorphism in the
ZFP90 gene is associated with systemic lupus erythematosus (SLE). In this study, we
explored the candidate function of a ZFP90 variant (rs1170426) in the context of SLE and
detected the relationship between SLE susceptible genes and SLE drug target genes.
First, we investigated the regulatory role of rs1170426 on ZFP90 expression by
expression quantitative trait loci (eQTL) analysis in peripheral blood mononuclear cells
(PBMCs), T, B, and monocytes cells and annotated the regulatory function of rs1170426
using bioinformatic databases. Second, we compared the case-control difference in
ZFP90 expression levels. Third, we analyzed the association of genotype and ZFP90
expression levels with SLE clinical characters. Last, we showed the interaction of SLE
susceptibility genes with SLE drug target genes. Subjects with the risk allele “C” of
rs1170426 had lower expression levels of ZFP90 in PBMCs (P = 0.006) and CD8+ T cells
(P = 0.003) from controls. SLE cases also had lower expression levels compared with
controls (P = 2.78E-9). After correction for multiple testing, the ZFP90 expression levels
were related to serositis (FDR p = 0.004), arthritis (FDR p = 0.020), hematological
involvement (FDR p = 0.021), and increased C-reactive protein (CRP) (FDR p = 0.005)
in cases. Furthermore, the SLE susceptible genes and the recognized SLE drug target
genes were more likely to act upon each other compared with non-SLE genetic genes
(OR = 2.701, P = 1.80E-5). These findings suggest that ZFP90 might play a role in the
pathogenesis of SLE, and SLE genetics would contribute to therapeutic drug discovery.
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Systemic lupus erythematosus (SLE) is a chronic multi-system
autoimmune disease that mostly affects women of childbearing
age (1). Though the pathogenesis of SLE is still unclear, inherited
susceptibility is an important aspect (2). The risk allele “C” of
rs1170426 was first identified to be significantly associated with
SLE in Han Chinese and European populations (Supplementary
Table 1) (3).
Zinc finger proteins (ZFP) are a diversified family of proteins
performing numerous biological functions (4), such as regulating
gene expression in many tissues (5). The expression of ZFP90 is
involved in various diseases, for example, colorectal cancer (6),
cardiac dysfunction (7), intellectual disability (8), and obesity (9).
In this study, we aimed to determine if rs1170426 was associated
with SLE pathogenesis by affecting the expression of ZFP90.
Previous studies have proved that the discoveries from GWAS
play a vital role in pharmaceutical development and drug
repositioning (10, 11). To assess the function of SLE genes in
pharmaceutical development, we also aimed to map the protein-
protein interaction (PPI) network between SLE susceptibility
genes and recognized SLE drug target genes, using the
drug database.METHODS
Subjects
To test the mRNA expression level of ZFP90, we recruited 135
SLE cases and 130 healthy controls. The demographic
characteristics of the samples included in the analysis were
summarized in Table 1. The genotyping and gene expression
study of four immune cells was conducted in 116 other healthy
controls. All subjects were Han Chinese and enrolled from the
First Affiliated Hospital of Anhui Medical University, Hefei,
Anhui Province, China. SLE cases were diagnosed by two or
more consultants in the Rheumatology or Dermatology
Department according to the revised American College ofFrontiers in Immunology | www.frontiersin.org 2Rheumatology (ACR) SLE classification criteria (12). All
clinical phenotypes of SLE cases were defined by the ACR SLE
classification criteria. The clinically verified healthy controls had
no history of SLE, family history of SLE, or any other
autoimmune diseases. Each subject signed informed consent to
participate in this study, which was performed following the
1964 Declaration of Helsinki and approved by the Ethical
Committee of Anhui Medical University.
Isolation of PBMCs, T Cells, B Cells,
and Monocytes
The whole bloodwas collected from the above subjects using an anti-
coagulation tube. We removed the plasma after centrifugal isolation
(RT, 400 × g, 5 min) and added an equal volume of phosphate-
buffered saline (PBS) to replace the removed plasma. The diluted
blood was layered onto Ficoll-Hypaque Solution. The PBMCs were
isolated by density-gradient centrifugation. The fresh PBMCs of 116
healthy controls were incubated for 15 min at 4°C with the following
fluorescent conjugated monoclonal antibodies: anti-CD3-FITC,
anti-CD14-PE, anti-CD19-APC, anti-CD4-PERCP-CY5.5, anti-
CD8-PE-CY7. Stained cells were sorted on a BD FACSAria III.
CD4+T, CD8+T, monocytes, and B cells were identified as CD4+/
CD3+, CD8+/CD3+, CD14+/CD3−, and CD19+/CD3−,
respectively. All stained cells were sorted to >98% purity.
Total RNA Isolation and qPCR
We extracted total mRNA from PBMCs and immune cell subsets
using TRIzol Reagent. After reverse transcription of RNA (400
ng of each sample, using the PrimeScript RT reagent Kit) isolated
from the samples, we used qPCR assays to confirm the relative
expression of ZFP90 mRNA in collected PBMCs. The
glyceraldehyde phosphate dehydrogenase (GAPDH) acted as
the internal control. Below primers were employed in the
qPCR: ZFP90 primers: forward 5′- CGCCCCAGGAAT
CAGTGACA -3′ and reverse 5′- GCTATAGTTCTCCAGC
ATCACATCC-3′. The experiment was conducted using the
ViiA 7 Real-Time PCR System. The level of ZFP90 mRNA
expression was computed using the 2-DDCt method (13).TABLE 1 | Demographic characteristics of the study subjects.
Characteristic SLE Cases n = 117 Healthy Controls n = 126 P
Gender
Female 109 125 /
Male 8 1 /
Age (years)1 37.23 ± 11.86 36.34 ± 9.33 /
Medications
Corticosteroids use 113 (96.6%) / /
Antimalarials use 74 (63.2%) / /
Immunosuppressive use 31 (26.5%) / /
Genotype 0.653
CC 4 (3.4%) 2 (1.6%) /
/
/
CT 34 (29.1%) 38 (30.2%)
TT 79 (67.5%) 86 (68.3%)
Allele 0.693
C 42 (17.9%) 42 (16.7%) /
/T 192 (82.1%) 210 (83.3%)March 2021 | Volume 12 | Article 61The age of the subjects is given at sample collection.
A P value is considered statistically significant if <0.05.11515
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We extracted the genomic DNA using a Wizard Genomic DNA
Purification Kit (QIAGEN, Germany). For 135 SLE cases and
130 healthy controls, we genotyped rs1170426 of each sample
using the improved multiplex ligation detection reaction
(iMLDR) technology. For 116 other healthy controls, we
genotyped each sample using Sanger sequencing. The
sequencing products were conducted on the ABI3730XL
automatic sequencer (Applied Biosystems).
Functional Annotation and Bioinformatic
Insights
We used HaploRegv4.1 (http://archive.broadinstitute.org/
mammals/haploreg/haploreg.php) (14) and rSNPBase (http://
rsnp.psych.ac.cn/) (15) databases to annotate the functional
elements containing rs1170426. We evaluated the effect of
rs1170426 on ZFP90 expression in SLE implicated tissues or
organs by using the Genotype-Tissue Expression (GTEx)
Analysis Release V8 (http://www.gtexportal.org/home/) (16). In
addition, we downloaded the RNA-seq data of EBV-transformed
lymphocytes from the website (http://ebv-b.helmholtz-
muenchen.de/) to address the influence of EBV infection on
ZFP90 expression (17). We used the WashU Epigenome Browser
(https://epigenomegateway.wustl.edu/) (18) to discover the
epigenomic regulatory potential of rs1170426.
The Association Between SLE
Susceptibility Genes and Drug
Target Genes
We got the target genes of SLE therapeutic drugs by consulting
the DrugBank database (https://www.drugbank.ca/) (19) and
Therapeutic target database (http://db.idrblab.org/ttd/) (20).
We extracted PPI information from InWeb (21) to evaluate
the potential relationship between SLE risk genes and drug target
genes. Furthermore, we obtained the PPI network of ZFP90 with
drug target genes by using the BioGRID database (https://
thebiogrid.org/) (22).
Statistical Analysis
We used one-way analysis of variance to evaluate the cis-eQTL
regulatory effect of rs1170426 on ZFP90 and compared ZFP90
mRNA expression levels in four kinds of immune cells. Mann-
Whitney U test was used to detect the case-control difference in
ZFP90 mRNA expression level, the correlation between ZFP90
mRNA expression level and clinical characteristics, the effect of
treatment on ZFP90 expression, as well as the difference in
ZFP90 mRNA expression level between cases and controls in
each rs1170426 genotype group, which did not conform to the
normal distribution. Chi-square test was applied to conduct
association analysis in our cohort, genotype-phenotype
analysis, and to analyze the difference of interaction probability
between SLE risk genes and non-risk genes with drug targets.
The PPI network diagram was plotted by Cytoscape software
(version v3.8.0). SPSS (version 26.0) software and GraphPad
Prism (version 8.01) were used for other data analysis and plotting.
For multiple testing, a false discovery rate (FDR) p-value of 0.05Frontiers in Immunology | www.frontiersin.org 3was used. The P-value (2 tails) of less than 0.05 indicated
statistical significance.RESULTS
Association of rs1170426 With ZFP90
mRNA Expression
To predict the regulatory function of rs1170426 on ZFP90
mRNA expression, we performed eQTL analysis in PBMCs,
CD4+ T, CD8+ T, CD14+ monocytes, and CD19+ B cells. As
shown in Figure 1A, the risk allele “C” of SNP rs1170426 was
correlated with lower expression levels of ZFP90 in PBMCs
extracted from healthy controls (P = 0.006). However, there
was no significant association in SLE cases (P = 0.548) (Figure
1B). Considering the medicine would affect eQTL, we grouped
the patients by medicine type (corticosteroids, antimalarials, and
immunosuppressive) and conducted eQTL analysis in each
group. The results are all negative (Supplementary Table 2).
In the four kinds of immune cells, we only found rs1170426 was
an eQTL for ZFP90 in CD8+ T cells (P = 0.003) (Figures 1C–F).
Detection of rs1170426 Regulatory Effects
The HaploReg v4.1 database showed rs1170426 located in the
intron of ZFP90 and overlapped with the binding site motifs of
the transcription factor CCCTC-Binding Factor (CTCF) and
Estrogen Receptor in T cells and monocytes (Table 2). It also
played the role of a regulatory element in T cells and monocytes, i.e.,
gene enhancers marked by histone modifications histone H3 lysine
4 trimethylation (H3K4me3). We further found 158 SNPs in strong
linkage disequilibrium (r2 > 0.8) with rs1170426 in the Asian
population. Among them, 135 SNPs were regarded as regulatory
SNPs (rSNPs) from SNPBase database. According to the GTEx
Portal (version v8), rs1170426 is a cis-eQTL impacting on the
expression of ZFP90 in EBV-transformed cells, sun-exposed skin,
not sun-exposed skin, and whole blood (P = 6.90E-8, P = 7.91E-2,
P = 1.60E-4, P = 1.13E-116, respectively) (Figure 2). By analyzing
the processed RNA-seq data of EBV transfected lymphocytes in
controls, we found that EBV transformation does not affect ZFP90
expression (Supplementary Figure 1). The epigenome annotation
results show that the variant rs1170426 is located in the enhancer
region of T cells and PBMCs respectively marked by H3 lysine 4
monomethylation (H3K4me1), H3K4me3, H3 lysine 9
trimethylation (H3K9me3), and H3 lysine 27 trimethylation
(H3K27me3). However, we did not observe the signal in B cells
(Figure 3A).
Difference in ZFP90 mRNA Expression
Levels
A total of 135 cases and 130 controls were collected for qPCR, 117
SLE cases and 126 healthy controls passed quality control for
inclusion in the subsequent analysis. The median level of ZFP90
mRNA expression in SLE cases [Q50 = 0.018 (Q25 = 0.013, Q75 =
0.027)] was 1.5 times lower than in healthy controls [0.027
(0.021,0.036)]. Accordingly, the mRNA expression level of ZFP90
was substantially decreased in SLE cases compared to healthyMarch 2021 | Volume 12 | Article 611515




FIGURE 1 | (A) The effect of rs1170426 on ZFP90 mRNA expression levels in PBMCs from healthy controls. Of the 126 controls, 10 individuals with CC, 38 with
CT, and 86 with TT were analyzed. The group with “CC” homozygous has the lowest expression levels (P = 0.006). (B) The effect of rs1170426 on ZFP90 mRNA
expression levels in PBMCs from SLE cases. Of the 117 cases, 4 individuals with CC, 33 with CT, and 79 with TT were analyzed. The expression did not significantly
correlate with genotype of rs2297550 (P = 0.548). (C–F) The effect of rs1170426 on ZFP90 mRNA expression levels in CD4+ T cells, CD8+ T cells, CD19+ B cells,
and CD14+ monocytes from other 110 healthy controls. Of the 110 controls, 3 individuals with CC, 23 with CT, and 84 with TT were analyzed. ZFP90 expression
levels of samples with risk allele “C” of rs1170426 were significantly decreased in CD8+ T cells (P = 0.003).TABLE 2 | Functional annotation of rs1170426.
SNP Chr Gene Risk allele Position (hg19) Function Enhancer histone marks LD-proxy of rSNP (r2 > 0.8)1 Motifs
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rSNP, rSNPBase identified regulatory SNPs.olume 12 | Article 611515
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into three groups by rs1170426 genotype and compared the case-
control ZFP90mRNA expression levels in each group, respectively.
The results showed that the ZFP90 mRNA expression levels of the
“CT” and “TT” groups were significantly decreased in cases (P =
0.004 and 1.836E-9, respectively). However, there is no statistical
significance in the “CC”group (P=0.800) (SupplementaryFigure2).
In addition, we compared the ZFP90 expression level between
patients with and without treatment by a certain class of drug
(corticosteroids, antimalarials, and immunosuppressive). The
results were not statistically significant (Supplementary Table 2).
At last, we found the ZFP90 mRNA expression levels was
remarkably different among four kinds of immune cells (P =Frontiers in Immunology | www.frontiersin.org 52.001E-56), including CD4+ T, CD8+ T, CD14+ monocytes, and
CD19+ B cells. Compared to other two types of cells, it especially
expressed higher in T cells (Figure 3C).
The Correlation Between ZFP90 mRNA
Expression and Clinical Characteristics
Compared with SLE cases without serositis, arthritis, or
hematological involvement, cases with these symptoms had
much lower levels of ZFP90 mRNA expression (FDR p =
0.004, FDR p = 0.020, FDR p = 0.021, respectively, Figure 4,
Table 3). Moreover, the expression level was also significantly
lower in cases with increased CRP than cases without a change in
CRP (FDR p = 0.005).FIGURE 2 | Plot showing the results of cis-eQTL analysis for SNP rs1170426 in EBV-transformed cells, sun-exposed skin, not sun-exposed skin, and whole blood
(P = 6.90E-8, P = 7.91E-2, P = 1.60E-4, P = 1.13E-116, respectively).A
B C
FIGURE 3 | (A)The epigenome annotation results of rs1170426 in T cells (green), B cells (red), and PBMCs (orange). The signal can be found in T cells and PBMCs,
while not in B cells. (B) The ZFP90 mRNA expression levels in four kinds of immune cells were remarkably different (P = 2.001E-56) and were higher in T cells.
(C) Compared the ZFP90 mRNA expression levels between SLE cases (n = 117, red) and healthy controls (n = 126, green) in PBMCs. The expression levels were
lower in cases than in healthy controls (P = 2.78E-9).March 2021 | Volume 12 | Article 611515
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Phenotype Analysis of rs1170426 and SLE
We found the frequency of the risk allele “C” in SLE cases was
higher than in healthy controls, however, there is no statistical
significance (Table 1). Then, we performed the genotype-phenotype
analysis in two steps. First, we analyzed the correlation between
genotype frequency and clinical character. Second, we conducted it
for allele frequency. We only discovered that rs1170426 was
statistically significant with arthritis involved (P = 0.037) (Table 4).
The PPI Information for SLE Susceptibility
Genes and Drug Target Genes
We summarized 86 published and putative SLE risk genes that
achieved genome-wide significance (P < 5.0E-8) (23, 24)
(Supplementary Table 3). We then discovered 41 SLE drug
target genes by the DrugBank database and Therapeutic target
database (Supplementary Table 4). From the Inweb database, 72
SLE susceptibility genes (without ZFP90) were found to have PPI
information with other genes, of which 29 were found to have
protein interactions with SLE drug-targeted genes (Figure 5A).
However, only 2,496 out of 12,491 SLE unassociated genes had
PPI information with SLE drug-targeted genes in the Inweb
database. Although only NFKBIA was mapped as both SLE risk
genes and SLE drug target genes, the probability of SLE drug-Frontiers in Immunology | www.frontiersin.org 6targeted genes interaction with SLE susceptibility genes was
much higher than unassociated genes (OR = 2.701, P = 1.80E-5)
(Figure 5A). In the BioGRID database, we further discovered
protein interaction between ZFP90 and PRKAB2, a drug target
gene of SLE (Figure 5B).DISCUSSION
SLE is a chronic autoimmune disease that often involves multiple
organs, and its pathogenesis is related to numerous signaling
pathways. GWAS is an efficient strategy to define disease
susceptibility variants (25, 26). Our team has detected that
rs1170426 located in the ZFP90 region is strongly linked to SLE
by a trans-ancestral GWAS meta-analysis (3). Nonetheless, its
potential causal effect and clinical relevance remain to be
investigated in SLE. In this study, we found rs1170426 was a cis-
eQTL for ZFP90 in PBMCs and primary CD8+T cells extracted
from healthy controls. SLE cases expressed markedly lower
transcriptional levels of ZFP90 compared with controls. After
correction for multiple testing, the ZFP90 expression levels were
still correlated with some clinical characters in cases. Importantly,
we mapped the protein-protein interaction (PPI) network between
SLE susceptibility genes and recognized SLE drug target genes.A B
DC
FIGURE 4 | (A) The ZFP90 mRNA expression levels were lower (FDR p = 0.004) in cases with serositis than those without. (B) The levels were lower (FDR p =
0.020) in cases with arthritis than those without. (C) The levels were lower (FDR p = 0.021) in cases with hematologic involvement than those without. (D) The levels
were lower (FDR p = 0.005) in cases with increased CRP than those without.March 2021 | Volume 12 | Article 611515
Zhu et al. ZFP90 Association With SLEZFP90 is a zinc-finger protein that contains 13 zinc finger
domains and a KRAB domain (27). The dysregulation of ZFP90
was associated with some autoimmune diseases, including
inflammatory bowel disease, vitiligo, and multiple sclerosis (3).
According to the expression data from GTEx, ZFP90 is widely
expressed in various tissues such as skin and whole blood. We
also confirmed it abundantly expressed in PBMCs and especially
in T cells. Through functional annotation using multiple
databases, we revealed that the variant rs1170426 had a
regulatory function on ZFP90. The SNP rs1170426 of ZFP90 is
predicted to span the binding site motifs of the transcription
factor CTCF and Estrogen Receptor in T cells and monocytes.
We also discovered rs1170426 was a cis-eQTL for ZFP90 in
healthy PBMCs and primary CD8+T cells. The CTCF has been
reported to take part in regulating the aberrant gene expression
in SLE T cells (28). The estrogen contributes to immune cell
trafficking and inflammation (29), which advances the
understanding of significant gender bias in SLE cases. These
findings provide essential clues to explore the relationship
between SLE and the variant rs1170426 of ZFP90.
ZFP90 has been reported to regulate the activation of Ca2+
channels to a certain extent (7). An increased and prolonged
Ca2+ influx was also observed in T cells of SLE patients (30).
Altered Ca2+ flux can cause mitochondrial dysfunction and
predispose to necrotic cell death (31). Increased cell necrosis may
trigger the pro-inflammatory status resulting from the production
of pro-inflammatory cytokines [such as TNF-a, interleukin-6 (IL-6)
and IL-8] and interferon (32).
We also found ZFP90 mRNA expression level was strongly
linked with clinical characteristics. It was significantly lowered inFrontiers in Immunology | www.frontiersin.org 7SLE cases with serositis than those without. Serositis is one of the
manifestations of lupus, which is often accompanied by the
presence of infections. The exact pathogenesis of SLE serositis
is still elusive. A study showed abnormal Ca2+ influx could lead
to an inflammatory response associated with the onset of
serositis (33). Our results also displayed that ZFP90 mRNA
expression level was lower in cases with arthritis than without.
A previous study has shown that arthritis affects no less than 90%
of SLE cases at some point during the course of the disease (34).
It has been reported that IL-6, related to ZFP90, can promote
arthritis and joint deformation in SLE cases (35). Consequently,
we can reasonably suspect that the low expression of ZFP90
promotes the production of pro-inflammatory factors leading to
the onset of arthritis. Besides, some studies have shown that pro-
inflammatory factors can stimulate the production of CRP (36,
37). Hence, in this study, SLE cases with a lower ZFP90 mRNA
expression level had an elevated CRP level. As we all know,
infection is a common and leading cause of morbidity and
mortality in SLE patients (38). CRP is generally associated with
infection. So we would imagine the lower expression of ZFP90
was associated with SLE through the infection pathway.
Hematopoietic stem cells (HSCs), which take on the potency
to self-renew and differentiate to all lineage blood cells, play an
essential role in hematopoiesis (39, 40). Studies have shown that
ZFP90 can be used as a transcription factor to participate in the
regulation of HSC self-renewal and repopulation potential in
vivo (41). Besides, excessive activation of the Wnt/b-catenin
signaling pathway, an important signal pathway to participate
in SLE (42), facilitates HSCs to lose the abilities of differentiation
(43, 44). SLE cases with low expression of ZFP90 are more likelyTABLE 3 | Association between ZFP90 mRNA expression levels and SLE clinical characteristics in cases.
Clinical characteristics Presence Absence FDRP
2
N1 Mean ± SD/Q50 (Q25,Q75) N Mean ± SD/Q50 (Q25,Q75)
SLEDAI3 ≥10 63 0.019 (0.013,0.030) 54 0.017 (0.013,0.022) 0.132
Clinical manifestations
Renal damage 77 0.019 (0.013, 0.026) 40 0.016 (0.012,0.025) 0.148
Malar rash 40 0.019 (0.013, 0.023) 77 0.018 (0.013, 0.023) 0.199
Discoid rash 14 0.018 (0.009,0.015) 103 0.018 (0.012,0.028) 0.199
Photosensitivity 10 0.024 (0.012,0.033) 107 0.017 (0.012,0.025) 0.165
Vasculitis 11 0.019 ± 0.010 106 0.018 (0.013,0.027) 0.191
Hematologic
involvement
52 0.016 (0.012,0.025) 65 0.019 (0.015,0.028) 0.021*
Arthritis 42 0.016 (0.012,0.024) 75 0.021 (0.015,0.031) 0.020*
Mucosal ulcers 14 0.016 (0.016,0.028) 103 0.018 (0.013,0.028) 0.074
Central nervous system involvement 8 0.017 ± 0.006 109 0.018 (0.013,0.027) 0.177
Serositis 20 0.013 (0.011,0.018) 97 0.019 (0.013,0.029) 0.004*
Cardiac involvement 17 0.015 (0.012,0.022) 100 0.018 (0.013,0.028) 0.137
Laboratory indicators
ANA (+) 114 0.017 (0.013,0.026) 3 0.065 ± 0.076 0.150
Anti-dsDNA (+) 66 0.018 (0.013,0.028) 51 0.017 (0.013,0.027) 0.206
Anti-SM (+) 59 0.018 (0.013,0.024) 58 0.018 (0.013,0.030) 0.200
Anti-RNP (+) 45 0.018 (0.014,0.027) 72 0.018 (0.013,0.028) 0.197
Increased CRP 66 0.015 (0.013,0.022) 51 0.021 (0.017,0.031) 0.005*
Increased ESR 90 0.017 (0.013,0.029) 27 0.018 (0.013,0.026) 0.200
Low complement 77 0.018 (0.013,0.028) 40 0.017 (0.013,0.024) 0.191March 2021 | Volume 12 | Article1The number of patients;
2 False Discovery Rate P value;
3Systemic Lupus Erythematosus Disease Activity Index;
*A FDRP value is considered statistically significant if <0.05.611515
Zhu et al. ZFP90 Association With SLEto have a hematologic abnormality, perhaps due to the loss of the
balance between proliferation and differentiation in HSCs.
In the PPI network of ZFP90 and SLE drug target genes,
ZFP90 interacts with PRKAB2. PRKAB2 can activate AMP-
activated protein kinase (AMPK) in response to Ca2+ increase
(45). ZFP90 also participates in the regulation of Ca2+ channelsFrontiers in Immunology | www.frontiersin.org 8and affects the flow of Ca2+ as mentioned above. This may
contribute to explain the relationship between ZFP90 and
PRKAB2. PRKAB2 is also one of the target genes of
Fostamatinib that is a drug approved by the US Food and
Drug Administration (FDA) in 2018 for the treatment of
idiopathic thrombocytopenic purpura. Fostamatinib has beenTABLE 4 | The results of genotype-phenotype analysis.
Clinical characteristics Genotype P1 Allele P
CC (4) CT (34) TT (79) C (42) T (192)
SLEDAI2≥10 23 17 44 0.907 21 105 0.661
Clinical manifestations
Renal damage 3 22 52 0.927 28 126 0.775
Malar rash 2 8 30 0.294 12 68 0.439
Discoid rash 0 4 10 0.590 4 24 0.608
Photosensitivity 1 1 8 0.238 3 17 0.738
Vasculitis 0 3 8 0.657 3 19 0.591
Hematologic
involvement
1 16 35 0.650 18 86 0.896
Arthritis 1 18 23 0.037* 20 64 0.065
Mucosal ulcers 1 6 7 0.307 8 20 0.107
Central nervous
system involvement
0 2 6 0.716 2 14 0.558
Serositis 1 5 14 0.843 7 33 0.975
Cardiac involvement 1 6 10 0.649 8 26 0.332
Laboratory indicators
ANA (+) 4 32 78 0.772 40 188 0.711
Anti-dsDNA (+) 3 20 43 0.622 26 106 0.353
Anti-SM (+) 3 16 40 0.590 22 96 0.639
Anti-RNP (+) 2 14 29 0.764 18 72 0.459
Increased CRP 3 14 49 0.122 20 112 0.247
Increased ESR 4 24 62 0.287 32 148 0.938
Low complement 2 23 52 0.730 27 127 0.937March 2021 | Volume 12 | Article 61If number <5, choose Fisher’s Exact Test, otherwise Person Chi-Square;
2Systemic Lupus Erythematosus Disease Activity Index;
3The number of patients with both the clinical phenotype and a certain genotype or allele;
*A P value is considered statistically significant if <0.05.A B
FIGURE 5 | (A) The plot shows the PPI network of putative SLE risk genes and SLE drug target genes. SLE risk genes are shown as light blue nodes and SLE
drugs target genes are shown as orange nodes. NFKBIA, which was shown as red node, is both SLE risk genes and SLE drug target genes. (B) This figure plots
the protein interaction between ZFP90 and drug-targeted genes. PRKAB2 is a SLE drug-targeted gene (circled in red).11515
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disease in lupus-prone mice (46). This find might promote that
Fostamatinib would be used for SLE patients in the future.
Choosing genetically supported targets can significantly
increase the success rate of clinical drug development (11),
which is supported by our analysis of the relationship between
SLE susceptibility genes and drug target genes.
The current study still has some caveats. The limited sample
size may weak the statistical power. Besides, as the real target
could be mapped far away from the associated variants (47), lists
of the causal genes for disease associations can be incomplete,
and inaccurate at times.
In summary, we have dissected the possible pathogenic role of
ZFP90 in SLE and its impact on related clinical characteristics.
Given the clinical characteristics, bioinformatics, and functional
significance of genetic variation and the defined functional target
gene, ZFP90, we draw the conclusion that the risk SNP locus of
rs1170426 and its associated pathways might be meaningful for
SLE, and targeting this pathway may be vital in the prevention or
treatment of SLE. In addition, we provide evidence that the SLE
genetics play important role in therapeutic drug discovery.
However, further studies will be needed to elucidate this further.DATA AVAILABILITY STATEMENT
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